p. 1149−1156
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1157−1162
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1163−1172
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1173−1185
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1187−1200
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1201−1215
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1217−1228
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1229−1235
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
G1, G3) (G3>G1). Conclusion:Capsaicin play an important role in reduction and prevention of transformation of epithelial dysplasia into malignant tumor especially oral squamous cell carcinoma. The liquid form of capsaicin may be considered as a new line of treatment in oral dysplasia or even in oral squamous cell carcinoma and the Bcl-2 expression evidenced this reduction of abnormality in epithelial dysplasia.]]>
p. 1237−1243
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
0.05). Likewise, in PRO and MXF groups, the salivary inflammatory marker (IL-1β) was significantly reduced in comparison to SRP group (p < 0.01). In all groups, salivary IL-1β levels were decreased at 6 and 12 weeks compared to baseline values. It was concluded that the adjunctive use of PRO and MXF to SRP had significantly improved the treatment outcomes in subjects with severe gP comparable to SRP alone. Thus, PRO and MXF showed promising results in the treatment of periodontal disease. KEYWORDS Propolis, Moxifloxacin, Adjunctive treatment, Periodontitis.]]>
p. 1245−1255
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1257−1266
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1267−1278
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1279−1290
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1291−1296
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1297−1309
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1311−1321
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1323−1328
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1329−1339
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1341−1348
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1349−1358
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1359−1366
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1367−1375
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1377−1387
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1389−1395
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1397−1401
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1403−1409
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)
p. 1411−1419
2090-2360
Vol.65/No.Issue 2 - April (Oral Medicine, X-Ray, Oral Biology & Oral Pathology)